Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla

BackgroundMutations in the isocitrate dehydrogenase enzyme are present in a majority of lower-grade gliomas and secondary glioblastomas. This mis-sense mutation results in the neomorphic reduction of isocitrate dehydrogenase resulting in an accumulation of the “oncometabolite” 2-hydroxyglutarate (2HG). Detection of 2HG can thus serve as a surrogate biomarker for these mutations, with significant translational implications including improved prognostication. Two dimensional localized correlated spectroscopy (2D L-COSY) at 7T is a highly-sensitive non-invasive technique for assessing brain metabolism. This study aims to assess tumor metabolism using 2D L-COSY at 7T for the detection of 2HG in IDH-mutant gliomas.MethodsNine treatment-naïve patients with suspected intracranial neoplasms were scanned at 7T MRI/MRS scanner using the 2D L-COSY technique. 2D-spectral processing and analyses were performed using a MATLAB-based reconstruction algorithm. Cross and diagonal peak volumes were quantified in the 2D L-COSY spectra and normalized with respect to the creatine peak at 3.0 ppm and quantified data were compared with previously-published data from six normal subjects. Detection of 2HG was validated using findings from immunohistochemical (IHC) staining in patients who subsequently underwent surgical resection.Results2HG was detected in both of the IDH-mutated gliomas (grade III Anaplastic Astrocytoma and grade II Diffuse Astrocytoma) and was absent in IDH wild-type gliomas and in a patient with breast cancer metastases. 2D L-COSY was also able to resolve complex and overlapping resonances including phosphocholine (PC) from glycerophosphocholine (GPC), lactate (Lac) from lipids and glutamate (Glu) from glutamine (Gln).ConclusionsThis study demonstrates the ability of 2D L-COSY to unambiguously detect 2HG in addition to other neuro metabolites. These findings may aid in establishing 2HG as a biomarker of malignant progression as well as for disease monitoring in IDH-mutated gliomas.

[1]  K. Ichimura.  Molecular pathogenesis of IDH mutations in gliomas , 2012, Brain Tumor Pathology.

[2]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[3]  Erwin G. Van Meir,et al.  Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma , 2012, Journal of Molecular Medicine.

[4]  G. Reifenberger,et al.  Patients with IDH 1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH 1-mutated glioblastomas , and IDH 1 mutation status accounts for the unfavorable prognostic effect of higher age : implications for classification of gliomas , 2010 .

[5]  Edward Pan,et al.  In vivo detection of 2‐hydroxyglutarate in brain tumors by optimized point‐resolved spectroscopy (PRESS) at 7T , 2017, Magnetic resonance in medicine.

[6]  Z. Bhujwalla,et al.  Choline phospholipid metabolism: A target in cancer cells? , 2003, Journal of cellular biochemistry.

[7]  R. Guillevin,et al.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.

[8]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[9]  H. Degani,et al.  Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies , 2007, International journal of cancer.

[10]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[11]  R. Gruetter,et al.  In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time , 1999, Magnetic resonance in medicine.

[12]  Mitchel S. Berger,et al.  Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.

[13]  G Friedmann,et al.  Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. , 1992, Radiology.

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Anil Kumar,et al.  Optimization of two-dimensional NMR by matched accumulation , 1991 .

[16]  Hai Yan,et al.  2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations , 2011, PloS one.

[17]  J Hennig,et al.  Human brain tumors: assessment with in vivo proton MR spectroscopy. , 1993, Radiology.

[18]  K. Garber.  Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. , 2010, Journal of the National Cancer Institute.

[19]  J. Nelson,et al.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.

[20]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[21]  Y. Kato,et al.  Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors , 2012, Journal of Neuro-Oncology.

[22]  Matthijs Oudkerk,et al.  1H MR Spectroscopy Detection of Lipids and Lactate in Metastatic Brain Tumors , 1996, NMR in biomedicine.

[23]  D. Louis,et al.  Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis , 2009, Acta Neuropathologica.

[24]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[25]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[26]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[27]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[28]  G. Sutherland,et al.  High‐Resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms , 1992, Magnetic resonance in medicine.

[29]  T. Mcknight,et al.  Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. , 2004, Seminars in oncology.

[30]  Peter Boesiger,et al.  ProFit: two‐dimensional prior‐knowledge fitting of J‐resolved spectra , 2006, NMR in biomedicine.

[31]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[32]  Akira Matsumura,et al.  Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing , 2011, Brain Tumor Pathology.

[33]  G. Mckhann,et al.  Why glioma patients seize: adding more pathological GABA to the glutamate hypothesis. , 2014, Neurosurgery.

[34]  Shoji Naruse,et al.  Evaluation of two‐dimensional L‐COSY and JPRESS using a 3 T MRI scanner: from phantoms to human brain in vivo , 2003, NMR in biomedicine.

[35]  F. Ducray,et al.  Predictive and prognostic factors for gliomas , 2011, Expert review of anticancer therapy.

[36]  C. Manelfe,et al.  Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. , 1999, Investigative radiology.

[37]  S. Gross,et al.  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. , 2012, ACS medicinal chemistry letters.

[38]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[39]  J. Koutcher,et al.  In vivo tumor lactate relaxation measurements by selective multiple‐quantum‐coherence (Sel‐MQC) transfer , 2004, Magnetic resonance in medicine.

[40]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[41]  Peter Jezzard,et al.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.

[42]  R. Deberardinis,et al.  Glutamine: pleiotropic roles in tumor growth and stress resistance , 2011, Journal of Molecular Medicine.

[43]  R Lufkin,et al.  Localized two‐dimensional shift correlated MR spectroscopy of human brain , 2001, Magnetic resonance in medicine.

[44]  J. Klein.  Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids , 2000, Journal of Neural Transmission.

[45]  R. Nanga,et al.  Implementation of two‐dimensional L‐COSY at 7 tesla: An investigation of reproducibility in human brain , 2014, Journal of magnetic resonance imaging : JMRI.

[46]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. J. van den Bent,et al.  IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide , 2009, Neurology.

[48]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[49]  A. Sorensen,et al.  Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma. , 2011, Radiology.